Open AccessGlucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide
Author(s) -
Richard J MacIsaac
Publication year - 2021
Publication title -
future cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.392
H-Index - 33
eISSN - 1744-8298
pISSN - 1479-6678
DOI - 10.2217/fca-2020-0210
Subject(s) - dulaglutide , medicine , type 2 diabetes , hazard ratio , diabetes mellitus , incretin , exenatide , sitagliptin , glucagon like peptide 1 , endocrinology , cardiology , confidence interval
Results from cardiovascular outcomes trials (CVOTs) in people with Type 2 diabetes (T2D), such as the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) study with dulaglutide, have led to a shift toward glucose lowering therapies that provide broad benefits, including cardiovascular (CV) risk reduction and renoprotection. Dulaglutide reduces atherosclerotic CV outcomes (hazard ratio 0.88; 95% CI: 0.79–0.99) and composite kidney outcomes (hazard ratio 0.85; 95% CI: 0.77–0.93) in people with T2D with high risk or established CV disease. The cardiologists’ role has now expanded to include not only screening for T2D and treating risk factors, but also recommending or incorporating glucose-lowering agents with proven CV benefit into the care of their patients with T2D.